logo
Scientists Startled by Discovery of Small Star Swimming Through Outer Layers of Another Larger Star

Scientists Startled by Discovery of Small Star Swimming Through Outer Layers of Another Larger Star

Yahoo2 days ago

A team of researchers in China have discovered a stunning binary system in which a stellar object known as a pulsar orbited inside the outer layers of its companion star — which it accomplished after stripping its host's innards and dispersing them into space.
The findings, detailed in a new study published in the journal Science, are an incredibly rare example of a "spider star" that preys on its companion, so-named because of the female arachnids that devour males after mating. And tantalizingly, the grisly scene is some of the best evidence yet of a stage of stellar evolution called the common envelope phase, which has never been directly observed by astronomers.
Pulsars are rapidly spinning neutron stars, the incredibly dense stellar cores that are left over in the aftermath of a supernova.
Everything about neutron stars exhaust superlatives — their gravity most of all. They are so tightly packed, containing more mass than our Sun inside a form just a dozen miles in radius, that all their atoms and their constituent protons and electrons have been crushed into neutrons, with just a teaspoon of this improbable matter weighing trillions of pounds. Their powerful magnetic fields, billions of times stronger than Earth's, unleash beams of radio waves into space along their poles.
Further beggaring belief, some neutron stars become pulsars, which spin up to hundreds of times per second after siphoning material from a stellar companion, if it has one. Their sweeping beams of radiation, like cosmic lighthouses, look like a repeating signal to observers.
The newly discovered pulsar, PSR J1928+1815, intrigued the astronomers because its radio pulses suggested that it was extremely close to its host, completing an orbit every 3.6 hours. They also noticed that for one-sixth of that orbit, the pulsar would vanish from view, indicating that the host was eclipsing it.
"That's a large part of the orbit," coauthor Jin-Lin Han, a radio astronomer at the National Astronomical Observatories in Beijing, told Gizmodo. "That's strange, only a larger companion can do this."
Over four and a half years, Han's team closely observed the system using the Five-hundred-meter Aperture Spherical Radio Telescope (FAST) in southern China, the largest and most powerful single-dish radio telescope in the world.
Their observations revealed that the host star was between one to 1.6 times the mass of our Sun, while the pulsar was more likely 1.4 stellar masses. Determining the make of the host star, however, took some additional sleuthing. Its tight orbit and the fact that it was only detectable in radio wavelengths, Giz noted, ruled out its being a Sun-like star. And since it was large enough to eclipse the pulsar, it had to be something larger than a stellar remnant like another neutron star.
That pointed to something altogether more spectacular: a helium star, created after the pulsar, when it was still an ordinary neutron star, tore off its host's layers and created a huge common envelope, a cloud of hydrogen gas that swallows both the stars. In this case, the poor star under attack managed to cling on to its evacuated innards for just 1,000 years — a blink in a stellar lifespan — before the whole, mighty envelope fell apart. Fleeting as it was, its impact is lasting: the friction exerted by the gases gradually nudged both stars closer together.
Common envelopes are rare because the process of a neutron star stripping its companion, which causes it to spin and graduate to a pulsar, usually results in all the siphoned material being devoured. But if the companion is massive enough, much of it survives.
The discovery marks the first spider star found orbiting a helium star. While the astronomers didn't get to witness the envelope in action, this is some of the most convincing evidence to date that this long-theorized stage of stellar evolution exists. In all, the team estimates that there're just 16 to 84 star systems like this one in the entire Milky Way — and, against all odds, we got to see one.
More on space: Scientists Puzzled by Mysterious Motion in Atmosphere of Saturn's Moon

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bright green meteor zooms past Sydney as auroras dazzle across Australia
Bright green meteor zooms past Sydney as auroras dazzle across Australia

Yahoo

timean hour ago

  • Yahoo

Bright green meteor zooms past Sydney as auroras dazzle across Australia

A bright green meteor was seen zooming past Sydney on Sunday as spectacular southern lights lit up the skies across most of Australia and New Zealand. A Sydney resident named Tom McCallister posted a video of the meteor, about the size of a basketball, traversing the city's skies. 'Absolutely magnificent meteor seen travelling east to west over Sydney this evening,' Mr McCallister captioned the video posted on Facebook. 'This was looking north at 17:57 local time.' Astrophysicist Brad Tucker, from the Australian National University, agreed that the object was indeed a meteor due to its unique blue-green colour, indicative of iron and nickel content. Anyone else just see a green, long meteor over Canberra? Tried to get a photo but I've only got slow shutter speeds on - out waiting for Aurora Australis instead - but that's a good start to the night! — Nat (@raurkyn) June 1, 2025 People across New Zealand and on Australia's east coast were also treated to a dazzling display of southern lights on Sunday. Many skygazers later shared photos of aurora australis on social media. The space weather phenomenon is caused when bursts of charged particles released from the Sun – known as coronal mass ejections, or CMEs – interact with the Earth's magnetic field, creating what's called a geomagnetic storm. The lights are called aurora australis in the southern hemisphere and aurora borealis in the northern hemisphere. Pictures posted on social media showed the sky glowing in hues of pink, red and green, with slight traces of yellow. The colours come from different molecules in the atmosphere getting charged by the Earth's magnetic field. Oxygen gives off a fluorescent green hue while nitrogen molecules interacting with the magnetic field generate a blue, red or pink shade. Auroras are seen when a strong solar storm from the Sun hits the Earth. They are more clearly visible around polar regions since the magnetic field is the strongest there. Aurora Australis dancing over Merimbula Lake in NSW, Australia this evening. — Fiona Brook (@The_Feefenator) June 1, 2025 Astronomers have predicted a strong geomagnetic storm on Sunday and Monday after a powerful CME was seen erupting from the Sun on Friday. The latest CME also caused aurora borealis across most of the continental US as far down south as Alabama. The US National Oceanic and Atmospheric Administration said the possibility of a severe geomagnetic storm remained 'in effect'. 'There are indications that the coronal mass ejection passage is weakening, but the solar wind conditions remain elevated, therefore additional periods of G3-G4 levels remain possible,' the NOAA said, using the designations for strong and severe category storms. 'However, we now anticipate that conditions should weaken enough by tomorrow evening, 2 June, that G1 storm levels are the most likely peak response.' The Sun is currently at the peak of its 11-year activity cycle.

J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025

Associated Press

time4 hours ago

  • Associated Press

J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025

Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea , June 1, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI drug candidate, at the American Society of Clinical Oncology 2025 (ASCO 2025), the world's largest oncology conference, held in Chicago, USA. JIN-A02 is an oral, fourth-generation EGFR-TKI designed to overcome resistance mutations (such as C797S) that develop after treatment failure with third-generation EGFR-TKIs, which are currently the first-line therapy for EGFR-mutant Non-small cell lung cancer (NSCLC). It is currently undergoing clinical trials in South Korea, the United States, Thailand, and other countries. Key efficacy and safety results from Part A (dose escalation) of the multi-center clinical trial (NCT05394831) were presented. 'Confirmed' clinical response observed in patients with disease progression after 3rd Generation EGFR TKI and chemotherapy One of the key findings of the ASCO presentation was that tumor responses were sustained in specific dose cohorts, with confirmed partial responses (PRs) verified by independent evaluation. Confirmed PRs were observed in 50mg,100mg and 300mg QD dose groups, providing clinical evidence of anti-tumor activity. In the 50 mg dose group, patients achieved a 77.3% reduction in tumor size, maintaining a PR over six consecutive treatment cycles (from cycle 3 to cycle 13). In the 300 mg dose group, a confirmed PR was observed with a 39.7% tumor size reduction, including a significant reduction in brain metastatic lesions. In the 100 mg dose group, a PR was also reported with a 35.3% reduction in tumor size, and brain metastatic lesions remained stable, further supporting the potential of JIN-A02 in treating brain metastases. Safety confirmed up to 300 mg, with therapeutic signals in brain metastases No dose-limiting toxicities (DLTs) or serious adverse events were observed with JIN-A02 at doses up to 300mg, which is six times the dose level when PR was first observed, demonstrating a favorable safety profile even at higher dose levels. The majority of adverse events reported at 300mg were mild (Grade 1-2) and included for the first time, Grade 1 skin rash, diarrhea, and skin desquamation in 3 out of 5 subjects – events commonly associated with EGFR inhibitors and generally considered clinically manageable. Importantly, there were no reports of systemic toxicities such as cardiovascular events or hepatotoxicity, supporting the drug's excellent safety profile. This safety and tolerability have translated into extended treatment durations in real-world settings, with a patient still on JIN-A02 after one year and seven months. In addition, the trial demonstrated notable responses in brain metastases first noted at 100mg, suggesting that JIN-A02 achieves therapeutically relevant concentrations in brain tissue. JIN-A02 gains national spotlight as government grants accelerate development In addition to the ASCO announcement, J INTS BIO continues to achieve noteworthy results in Korea. Recently, it was selected for the '2025 Baby Unicorn Fostering Project' by the Ministry of SMEs and Startups, officially recognizing both our scientific technology and commercialization potential. The 'Baby Unicorn Fostering Project' is a government project that focuses on developing promising startups with innovative technologies and growth potential in the global market as 'potential unicorns'. Companies selected for this project will receive full government support in recognition of their technological prowess and growth potential. With these accolades, JIN-A02 will receive dual funding for its Phase 2 trial and global expansion over the next two years, which is expected to be a decisive point to significantly accelerate the pace of clinical and commercialization in parallel with private investment. It is also significant as a case of securing confidence in the 3 arena of technology, marketability, and global scalability, as the recognition came from different government departments. Based on these achievements, we plan to initiate the Phase 2 clinical trial of JIN-A02 in before the end of this year, in discussions with the US FDA. 'The ASCO presentation of JIN-A02's ability to induce anti-cancer responses and its ability to respond to central nervous system metastatic lesions is of great significance,' said Dr. Anna Jo, CEO. 'The government's continued support is a recognition of our technical capabilities and potential for growth. We will take advantage of this opportunity to accelerate global clinical expansion, technology transfer, and indication expansion to realize our goal of early commercialization' View original content to download multimedia: SOURCE J INTS BIO

J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025

Yahoo

time5 hours ago

  • Yahoo

J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025

Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea , June 1, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI drug candidate, at the American Society of Clinical Oncology 2025 (ASCO 2025), the world's largest oncology conference, held in Chicago, USA. JIN-A02 is an oral, fourth-generation EGFR-TKI designed to overcome resistance mutations (such as C797S) that develop after treatment failure with third-generation EGFR-TKIs, which are currently the first-line therapy for EGFR-mutant Non-small cell lung cancer (NSCLC). It is currently undergoing clinical trials in South Korea, the United States, Thailand, and other countries. Key efficacy and safety results from Part A (dose escalation) of the multi-center clinical trial (NCT05394831) were presented. 'Confirmed' clinical response observed in patients with disease progression after 3rd Generation EGFR TKI and chemotherapy One of the key findings of the ASCO presentation was that tumor responses were sustained in specific dose cohorts, with confirmed partial responses (PRs) verified by independent evaluation. Confirmed PRs were observed in 50mg,100mg and 300mg QD dose groups, providing clinical evidence of anti-tumor activity. In the 50 mg dose group, patients achieved a 77.3% reduction in tumor size, maintaining a PR over six consecutive treatment cycles (from cycle 3 to cycle 13). In the 300 mg dose group, a confirmed PR was observed with a 39.7% tumor size reduction, including a significant reduction in brain metastatic lesions. In the 100 mg dose group, a PR was also reported with a 35.3% reduction in tumor size, and brain metastatic lesions remained stable, further supporting the potential of JIN-A02 in treating brain metastases. Safety confirmed up to 300 mg, with therapeutic signals in brain metastases No dose-limiting toxicities (DLTs) or serious adverse events were observed with JIN-A02 at doses up to 300mg, which is six times the dose level when PR was first observed, demonstrating a favorable safety profile even at higher dose levels. The majority of adverse events reported at 300mg were mild (Grade 1-2) and included for the first time, Grade 1 skin rash, diarrhea, and skin desquamation in 3 out of 5 subjects – events commonly associated with EGFR inhibitors and generally considered clinically manageable. Importantly, there were no reports of systemic toxicities such as cardiovascular events or hepatotoxicity, supporting the drug's excellent safety profile. This safety and tolerability have translated into extended treatment durations in real-world settings, with a patient still on JIN-A02 after one year and seven months. In addition, the trial demonstrated notable responses in brain metastases first noted at 100mg, suggesting that JIN-A02 achieves therapeutically relevant concentrations in brain tissue. JIN-A02 gains national spotlight as government grants accelerate development In addition to the ASCO announcement, J INTS BIO continues to achieve noteworthy results in Korea. Recently, it was selected for the '2025 Baby Unicorn Fostering Project' by the Ministry of SMEs and Startups, officially recognizing both our scientific technology and commercialization potential. The 'Baby Unicorn Fostering Project' is a government project that focuses on developing promising startups with innovative technologies and growth potential in the global market as 'potential unicorns'. Companies selected for this project will receive full government support in recognition of their technological prowess and growth potential. With these accolades, JIN-A02 will receive dual funding for its Phase 2 trial and global expansion over the next two years, which is expected to be a decisive point to significantly accelerate the pace of clinical and commercialization in parallel with private investment. It is also significant as a case of securing confidence in the 3 arena of technology, marketability, and global scalability, as the recognition came from different government departments. Based on these achievements, we plan to initiate the Phase 2 clinical trial of JIN-A02 in before the end of this year, in discussions with the US FDA. "The ASCO presentation of JIN-A02's ability to induce anti-cancer responses and its ability to respond to central nervous system metastatic lesions is of great significance," said Dr. Anna Jo, CEO. "The government's continued support is a recognition of our technical capabilities and potential for growth. We will take advantage of this opportunity to accelerate global clinical expansion, technology transfer, and indication expansion to realize our goal of early commercialization" View original content to download multimedia: SOURCE J INTS BIO Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store